[1] HOWLADER N,NOONE A M,KRAPCHO M,et al.SEER Cancer statistics review,1975-2010,National Cancer Institute[EB/OL].http://seer.cancer.gov/csr/1975-2010.
[2] 谢玲玲,林仲秋.《2015美国肿瘤综合协作网子宫肿瘤临床实践指南(第2版)》解读[J].中国实用妇科与产科杂志,2015,31(1):5-9.
[3] BENDER D,SILL M W,LANKES H A,et al.A Phase Ⅱ evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer:an Nrg Oncology/Gynecologic Oncology Group Study[J].Gynecol Oncol,2015,138(3):507-512.
[4] AGHAJANIAN C,SILL M W,DARCY K M,et al.Phase Ⅱ trial of bevacizumab in recurrent or persistent endometrial cancer:a Gynecologic Oncology Group study[J].J Clin Oncol,2011,29(16):2259-2265.
[5] POWELL M A,SILL M W,GOODFELLOW P J,et al.A Phase Ⅱ trial of brivanib in recurrent or persistent endometrial cancer:an Nrg Oncology/Gynecologic Oncology Group Study[J].Gynecol Oncol,2014,135(1):38-43.
[6] CASTONGUAY V,LHEUREUX S,WELCH S,et al.A Phase Ⅱ trial of sunitinib in women with metastatic or recurrent endometrial carcinoma:a study of the Princess Margaret,Chicago and California Consortia[J].Gynecol Oncol,2014,134(2):274-280.
[7] OZA A M,EISENHAUER E A,ELIT L,et al.Phase Ⅱ study of erlotinib in recurrent or metastatic endometrial cancer:ncic ind-148[J].J Clin Oncol,2008,26(26):4319-4325.
[8] LESLIE K K,SILL M W,LANKES H A,et al.Lapatinib and potential prognostic value of Egfr mutations in a Gynecologic Oncology Group Phase Ⅱ Trial of persistent or recurrent endometrial cancer[J].Gynecol Oncol,2012,127(2):345-350.
[9] KONECNY G E,FINKLER N,GARCIA A A,et al.Second-line dovitinib(Tki258)in patients with Fgfr2-mutated or Fgfr2-non-mutated advanced or metastatic endometrial cancer:a Non-Randomised,Open-Label,Two-Group,Two-Stage,Phase 2 Study[J].The Lancet Oncology,2015,16(6):686-694.
[10] LESLIE K K,SILL M W,FISCHER E,et al.A phase Ⅱ evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer:a Gynecologic Oncology Group study[J].Gynecol Oncol,2013,129(3):486-494.
[11] DIZON D S,SILL M W,SCHILDER J M,et al.A Phase Ⅱ evaluation of nintedanib(Bibf-1120)in the treatment of recurrent or persistent endometrial cancer:an Nrg Oncology/Gynecologic Oncology Group Study[J].Gynecol Oncol,2014,135(3):441-445.
[12] TEMKIN S M,YAMADA S D,FLEMING G F,et al.A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies[J].Gynecol Oncol,2010,117(3):473-476.
[13] RAY-COQUARD I,FAVIER L,WEBER B,et al.Everolimus as second-or third-line treatment of advanced endometrial cancer:endorad,a phase Ⅱ trial of Gineco[J].Br J Cancer,2013,108(9):1771-1777.
[14] ACEVEDO-GADEA C,SANTIN A D,HIGGINS S A,et al.Phase I clinical trial of the mammalian target of rapamycin Inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer[J].Int J Gynecol Cancer,2014,24(3):528-533.
[15] COLOMBO N,McMEEKIN D S,SCHWARTZ P E,et al.Ridaforolimus as a single agent in advanced endometrial cancer:results of a single-arm,phase 2 trial[J].Br J Cancer,2013,108(5):1021-1026.
[16] TSOREF D,WELCH S,LAU S,et al.Phase Ⅱ study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer[J]Gynecol Oncol,2014,135(2):184-189.
[17] COLEMAN R L,SILL M W,THAKER P H,et al.A phase Ⅱ evaluation of selumetinib(Azd6244,Arry-142886),a selective Mek-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer:an Nrg Oncology/Gynecologic Oncology Group Study[J].Gynecol Oncol,2015,138(1):30-35.
[18] MATULONIS U,VERGOTE I,BACKES F,et al.Phase Ⅱ study of the Pi3k inhibitor pilaralisib(Sar245408;Xl147)in patients with advanced or recurrent endometrial carcinoma[J].Gynecol Oncol,2015,136(2):246-253.
[19] SIMPKINS F,DRAKE R,ESCOBAR P F,et al.A phase Ⅱ trial of paclitaxel,carboplatin,and bevacizumab in advanced and recurrent endometrial carcinoma(EMCA)[J].Gynecol Oncol,2015,136(2):240-245.
[20] COLEMAN R L,SILL M W,LANKES H A,et al.A phase Ⅱ evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer:a Gynecologic Oncology Group study[J].Gynecol Oncol,2012,127(3):538-543.
[21] MOORE K N,SILL M W,TENNEY M E,et al.A phase Ⅱ trial of trebananib(AMG 386;IND#111071),a selective angiopoietin 1/2 neutralizing peptibody,in patients with persistent/recurrent carcinoma of the endometrium:an NRG/Gynecologic Oncology Group trial[J].Gynecol Oncol,2015,138(3):513-518. |
